Endo International PLC (ENDP) Receives $14.02 Average Price Target from Brokerages
Endo International PLC (NASDAQ:ENDP) has earned an average rating of “Hold” from the twenty-four ratings firms that are presently covering the stock, Marketbeat reports. Three equities research analysts have rated the stock with a sell rating, sixteen have given a hold rating and five have given a buy rating to the company. The average 1 year price target among analysts that have covered the stock in the last year is $14.02.
Several analysts recently issued reports on the company. Stifel Nicolaus downgraded Endo International PLC from a “buy” rating to a “hold” rating and cut their price target for the stock from $22.00 to $15.00 in a report on Friday, June 9th. Oppenheimer Holdings, Inc. reiterated a “hold” rating on shares of Endo International PLC in a research report on Thursday, June 8th. Canaccord Genuity set a $12.00 price target on Endo International PLC and gave the company a “hold” rating in a research report on Thursday, June 8th. ValuEngine cut Endo International PLC from a “buy” rating to a “hold” rating in a research report on Friday, June 2nd. Finally, Mizuho reiterated a “buy” rating and set a $19.00 price target (up from $18.00) on shares of Endo International PLC in a research report on Thursday, May 25th.
Shares of Endo International PLC (NASDAQ:ENDP) traded up 0.23% during trading on Friday, hitting $8.56. 4,321,183 shares of the stock were exchanged. The stock’s market cap is $1.91 billion. The firm has a 50 day moving average of $9.45 and a 200-day moving average of $11.07. Endo International PLC has a 52-week low of $7.41 and a 52-week high of $23.98.
Endo International PLC (NASDAQ:ENDP) last released its earnings results on Tuesday, August 8th. The company reported $0.93 EPS for the quarter, topping analysts’ consensus estimates of $0.74 by $0.19. Endo International PLC had a positive return on equity of 37.58% and a negative net margin of 126.93%. The company had revenue of $875.73 million for the quarter, compared to the consensus estimate of $832.66 million. During the same quarter last year, the business posted $0.86 EPS. Endo International PLC’s quarterly revenue was down 4.9% compared to the same quarter last year. Equities research analysts anticipate that Endo International PLC will post $3.51 earnings per share for the current fiscal year.
In other Endo International PLC news, CFO Blaise Coleman bought 6,500 shares of the stock in a transaction dated Tuesday, August 15th. The shares were bought at an average cost of $7.89 per share, with a total value of $51,285.00. Following the completion of the acquisition, the chief financial officer now owns 13,729 shares of the company’s stock, valued at $108,321.81. The purchase was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, COO Terrance J. Coughlin bought 20,000 shares of the stock in a transaction dated Thursday, August 10th. The shares were acquired at an average cost of $7.70 per share, for a total transaction of $154,000.00. Following the completion of the acquisition, the chief operating officer now directly owns 181,369 shares of the company’s stock, valued at approximately $1,396,541.30. The disclosure for this purchase can be found here. Insiders have acquired 36,000 shares of company stock valued at $279,460 over the last 90 days. Company insiders own 0.50% of the company’s stock.
Several institutional investors and hedge funds have recently made changes to their positions in ENDP. OppenheimerFunds Inc. increased its stake in Endo International PLC by 182.9% in the first quarter. OppenheimerFunds Inc. now owns 2,873,153 shares of the company’s stock valued at $32,065,000 after acquiring an additional 1,857,678 shares during the last quarter. Bank of New York Mellon Corp boosted its position in Endo International PLC by 38.7% in the first quarter. Bank of New York Mellon Corp now owns 2,271,111 shares of the company’s stock valued at $25,345,000 after buying an additional 633,904 shares in the last quarter. Teachers Advisors LLC boosted its position in Endo International PLC by 1.9% in the second quarter. Teachers Advisors LLC now owns 840,470 shares of the company’s stock valued at $9,388,000 after buying an additional 15,928 shares in the last quarter. TIAA CREF Investment Management LLC boosted its position in Endo International PLC by 1.6% in the second quarter. TIAA CREF Investment Management LLC now owns 649,535 shares of the company’s stock valued at $7,255,000 after buying an additional 10,387 shares in the last quarter. Finally, Schneider Capital Management Corp boosted its position in Endo International PLC by 14.9% in the first quarter. Schneider Capital Management Corp now owns 642,311 shares of the company’s stock valued at $7,168,000 after buying an additional 83,100 shares in the last quarter. 90.74% of the stock is currently owned by institutional investors.
About Endo International PLC
Endo International PLC, formerly Endo Health Solutions Inc is a specialty healthcare solutions company focused on branded and generic pharmaceuticals, devices and services. The Company has a portfolio of branded pharmaceuticals that includes brands, such as Lidoderm, Opana ER, Voltaren Gel, Percocet, Frova, Supprelin LA, Vantas, Valstar and Fortesta Gel.
Receive News & Stock Ratings for Endo International PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International PLC and related stocks with our FREE daily email newsletter.